Therefore, the effect of ATRi after the knock-down of ARID1A expression was evaluated in two different ARID1A+ CRC cell lines (HCT15 and HCT116) to assess the effect of different genetic background on the treatment response (Supplement Figure S3). The gene discussed is ARID1A; the disease is colorectal carcinoma.